Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center Phase 2 Trial of Denosumab in the Treatment of Relapsed or Plateau-Phase Multiple Myeloma

NCT00259740 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00259740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00259740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center Phase 2 Trial of Denosumab in the Treatment of Relapsed or Plateau-Phase Multiple Myeloma
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
December 31, 2011
Enrollment
96 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or plateau-phase multiple myeloma